Biote (BioTE Medical)
Pellet-Therapy Training and Licensing Franchise
Evidence grade 3 of 5, Mixed. Read how the Atlas grades evidence.
The written rationale for this grade is still being prepared.
- FDA
- Compounded pellets; Testopel is FDA-approved; training/licensing model is commercial, not FDA-regulated
Reference only. Not medical advice.
What can go wrong
The primary clinical concern with pellet therapy is that dose cannot be titrated or removed easily after implantation, if levels run too high (e.g., polycythemia, supraphysiological testosterone), the pellet must wear off or be surgically removed. Insertion-site complications (infection, extrusion, bleeding) are documented. Standard TRT monitoring and fertility caveats apply.
This is something to take to a clinician. The Atlas can tell you what is known about biote (biote medical) in general. It cannot tell you what is happening in your body, and the difference matters most for exactly the symptoms that bring people to this page.
Biote (formerly BioTE Medical; publicly traded as Nasdaq: BTMD since a 2022 SPAC merger) describes itself as the largest hormone-optimization (pellet-therapy) training and certification company. Per Biote's own disclosures, certified providers pay fees, complete training, and agree to source pellets and supplements from approved Biote vendors. Biote earns service fees realized when certified practitioners perform pellet procedures; practices charge patients roughly $300-$700 per insertion, typically every 3-6 months. The model channels recurring revenue to Biote through the practices it certifies and supplies.
Markets itself as the largest pellet-therapy training company, revenue from certifying physicians and supplying pellets.
What people take it for
These are the reasons people give for taking it. They are not effects it has been shown to have.
How it is supposed to work
Testosterone pellets are implanted subcutaneously and release hormone over months. Biote's commercial model layers on top: it trains and licenses physicians, then sells them branded pellets that practices implant in patients for a per-insertion fee.
Subcutaneous pellets (compounded, or the FDA-approved Testopel) are implanted in the hip/buttock area via a small trocar incision and release testosterone over 3-6 months.
The structure behind the implant
Biote's revenue comes from physician training/certification fees and from selling branded pellets to those practices, which then bill patients $300-$700 per insertion several times a year. This aligns the company's revenue with the volume of insertions performed by its certified network.
Safety in detail
Pellet TRT requires clinician evaluation and monitoring. The inability to titrate or quickly remove dose after implantation is a documented concern not always disclosed in marketing.
What it does to fertility
Exogenous testosterone delivered by pellet suppresses spermatogenesis and can impair fertility.
What has to be monitored
The bloodwork this needs, and the reason it belongs with a clinician rather than a website.
- Total/free testosterone
- Hematocrit (polycythemia risk)
- PSA (age-appropriate)
- Estradiol
- Insertion-site assessment
What people get wrong
Nothing recorded here yet. There is almost certainly something people get wrong about this one, and the blank space means we have not written it down, not that the record is clean.
Who profits, and who pushes back
Nobody is named here yet, because we have not done that work on this entry. Read that as unfinished. Somebody almost certainly sells this, and somebody almost certainly disputes it. Assume both until we have checked.
Biote profits from physician training/certification fees and branded-pellet sales; certified practices profit from per-insertion fees; both rise with insertion volume.
At a glance
- Former name
- BioTE Medical
- Model
- Physician training, certification, and pellet supply
- Patient charge
- $300-$700 per insertion
- Insertion cadence
- Every 3-6 months
- Pellet requirement
- Practices must use Biote-brand pellets
What this entry does not yet cover
What follows is unfinished work on our side, not a finding about Biote (BioTE Medical). A short entry is not a safe entry.
- Timeline. We have not built the dated record of research and regulatory events.
- Cost and market. We have not documented what it sells for or who sells it.
- Supply chain. We have not mapped where it is made.
- Who uses it. We have not documented the user groups.
- What could change. No forward-looking summary yet.
- How it compares. We have not set it against the alternatives.
- Children and teenagers. We have not checked what is known about younger people.
Sources
No sources recorded for this entry yet. Nothing on this page can be checked against a citation until that changes, so treat it as a summary awaiting its evidence.